MK-677 dosage: what the trials actually used

MK-677 dosing is unusually simple to summarize, because the trials converged on one regimen and largely stayed there. The harder truth sits underneath it: there is no approved MK-677 product, so “the dose” means “the dose researchers used,” not a dose any regulator has sanctioned. For what the drug actually does at that dose, start with the MK-677 evidence monograph.

The dose the trials used: 25 mg, once daily, oral

Across the human literature — the 2-year older-adult trial, the obese-men study, the Alzheimer’s trial, the hip-fracture trial — the dose was the same: 25 mg once daily, taken by mouth.^[1][3] MK-677 is long-acting, so a single daily dose is enough to keep IGF-1 elevated around the clock; that’s part of its appeal versus injectables that have to be timed.

Why 25 mg: the dose-finding data

The 25 mg figure isn’t arbitrary. A dose-finding study in healthy elderly subjects compared 2 mg, 10 mg and 25 mg once daily.^[2] The 25 mg dose was the one that raised 24-hour GH by about 97% and lifted IGF-1 from a baseline of 141 up into the young-adult range — 219 µg/L at two weeks and 265 µg/L at four weeks.^[2] Lower doses moved the needle less. That is why later trials standardized on 25 mg.

It works on a timescale of weeks

One practical point the numbers make clear: MK-677 is not an acute drug. IGF-1 rises progressivelyover the first weeks of daily dosing — roughly a 60% rise by six weeks in one large trial, holding through twelve months.^[4] The flip side is that its metabolic downside (rising fasting glucose) builds over the same period, which is why it’s a drug to monitor, not to micro-dose casually. The fuller risk picture is in our side effects breakdown.

The honest bottom line

If you reduce it to what the evidence supports: MK-677 was studied at 25 mg once daily by mouth, the dose that reliably raised GH and IGF-1, with the effect building over the first month.^[1][2] But there is no approved dose, the trials that used 25 mg also surfaced metabolic and cardiac safety signals, and the real-world product is unregulated. Any decision to use it — and at what dose — belongs with a clinician who can monitor IGF-1 and fasting glucose, not with a forum post. See also MK-677 vs sermorelin.